PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease ReportsCastration-resistant prostatic neoplasms
MeSH D064129 - castration-resistant prostatic neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D011471:Prostatic neoplasms
$
Success rate
D064129: 
Castration-resistant prostatic neoplasms
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Accord HealthcareAbiraterone Abiraterone Accord  2021-04-26   
Cabazitaxel Cabazitaxel Accord  2020-08-28   
Amneal PharmaceuticalsAbiraterone Abiraterone  2019-01-07   
ApotexAbiraterone Abiraterone  2018-10-31   
BayerDarolutamide Nubeqa  2020-03-27   
Dr Reddys LaboratoriesAbiraterone Abiraterone  2020-05-18   
Florida Pharmaceutical ProductsAbiraterone Abiraterone  2023-03-23   
Glenmark PharmaceuticalsAbiraterone Abiraterone  2019-10-16   
Hikma PharmaceuticalsAbiraterone Abiraterone  2018-10-31   
Johnson & JohnsonAbiraterone Zytiga  2011-04-28 $575 M Q2/24-Q1/25 
Niraparib, Abiraterone Akeega 2027-08-12 2023-08-11   
KrkaAbiraterone Abiraterone Krka  2021-06-24   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
52%
68/132
Phase 2
27%
31/116
Phase 3
32%
12/37
Approved: 3Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bayer
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use